Group items tagged

FDA is an agency within the Department of Health and Human Services1 and consists of centers and offices responsible for protecting the public health by assuring the safety, efficacy, and security of human and veterinary drugs, biological products, medical devices, our nation's food supply, cosmetics, and products that emit radiation.

FDA Food and Drug Administration - Index to Drug-Specific Information - This Index does not include all FDA approved drugs. It only includes drugs that have been the subject of a Healthcare Professional Information sheet, an Early Communication About an Ongoing Safety Review, or other important information. Please use Drugs@FDA to search for information on a drug not found in the Index.

CBER is the Center within FDA that regulates biological products for human use under applicable federal laws, including the Public Health Service Act and the Federal Food, Drug and Cosmetic Act. CBER protects and advances the public health by ensuring that biological products are safe and effective and available to those who need them. CBER also provides the public with information to promote the safe and appropriate use of biological products.

Study to determine if a therapy regiment of the medication Hemin can improve symptoms in diabetic patients with gastroparesis (slow gastric emptying). We want to test the effects of this new medication on the rate at which food empties from your stomach and on your symptoms

"This is an update of the review "Feed thickener for newborn infants with gastro-oesophageal reflux" published in The Cochrane Library, Issue 3, 2002 (Huang 2002)."

Cascade Dafo,, Inc - www.cascadedafo.com - Helping Kids Lead Healthier, Happier Lives. Leader in design, innovation and manufacture of dynamic orthoses for children and adults. Introduced the first DAFO® (Dynamic Ankle Foot Orthoses) over twenty-five years ago.

Completed study on Motilin, a peptide, whose action is controlled by motilin receptors located in the gut. Action of Motilin at motilin receptors increases the gastric emptying rate (rate of emptying of food and fluid from the stomach). Compounds which stimulate motilin receptors therefore provide a potential approach to the treatment of a range of clinical conditions where delayed gastric emptying may contribute to symptoms, such as enteral feeding ntolerance (post-operative or intensive care patients), gastroparesis, diabetic gastroparesis, and functional dyspepsia. This study is the First Time In Human study for the motilin receptor agonist, GSK962040.